This content is first seen at Medscape Medical News
Disclaimer: The information provided in this site is correct at the time of publication. POMConnect assumes no responsibility or liability for any errors or omissions in the content of this site.
This news serves as an update for the prior news seen on:
https://www.pomconnect.com/news/long-term-use-of-certain-reflux-medications-is-associated-with-a-higher-risk-of-dementia-study-suggests/: No Link Between PPIs and Dementia in New Study
SUMMARY:
A recent study offers reassurance regarding the safety of long-term use of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) in older adults, as it found no increased risk of dementia or cognitive changes associated with these medications.
RESEARCH APPROACH:
This study was conducted as a post hoc observational analysis within the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial. It involved 18,934 adults aged 65 and above from the United States and Australia who did not have dementia when the study began. Of these participants, 25% were PPI users, and 2% were H2RA users at the start of the study. The researchers tracked the use of PPIs and H2RAs, the incidence of dementia, and cognitive changes over time.
KEY FINDINGS:
In a comprehensive analysis, it was determined that baseline PPI use did not increase the risk of developing dementia (hazard ratio [HR] of 0.88) or cognitive impairment (HR of 1.00). Additionally, there was no connection between PPI use and changes in overall cognitive test scores over the course of the study (ฮฒ -0.002). Furthermore, no associations were identified between H2RA use and cognitive outcomes.
PRACTICAL IMPLICATIONS:
The study team concludes that the prolonged use of PPIs in older adults is unlikely to have adverse effects on cognitive function.
RESEARCH TEAM AND SOURCE:
Conducted by Dr. Raaj Mehta, MD, PhD, affiliated with Massachusetts General Hospital and Harvard Medical School in Boston, this study was published online on June 12 in the journal Gastroenterology. Funding for the research was provided by grants from the National Institute on Aging, the National Cancer Institute, and other institutions.
LIMITATIONS:
It’s important to note that this study has limitations, including the potential for residual confounding and underestimation of PPI and H2RA use, a lack of data regarding medication dosage and duration, and the absence of information on ApoE4 allele status.
Link to the full News (Medscape Medical News):
